Information Collection; Payments, 16268-16269 [2019-07816]
Download as PDF
16268
Federal Register / Vol. 84, No. 75 / Thursday, April 18, 2019 / Notices
20190338 ......
20190360 ......
G
G
Greenbriar Equity Fund IV, L.P.; BDP International, Inc.; Greenbriar Equity Fund IV, L.P.
Altair Engineering Inc.; Datawatch Corporation; Altair Engineering Inc.
11/28/2018
20190296 ......
20190327 ......
20190329 ......
G
G
G
KK GP; Agnaten SE; KK GP.
William Goldring; Diageo plc; William Goldring.
Vista Equity Partners Fund VI, L.P.; Apptio, Inc.; Vista Equity Partners Fund VI, L.P.
11/29/2018
20190311
20190312
20190336
20190339
20190345
20190212
20190332
20190347
20190350
20190351
20190352
20190353
20190355
20190357
20190359
20190367
20190375
20190377
20190388
20190389
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
20190390 ......
20190396 ......
G
G
IFM Global Infrastructure Fund; Vitol Holding B.V.; IFM Global Infrastructure Fund.
Vitol Investment Partnership II Limited; VJVCo; Vitol Investment Partnership II Limited.
Hexagon Composites ASA; AFS Holdco, LLC; Hexagon Composites ASA.
Arcosa, Inc.; H.I.G. Capital Partners IV, L.P.; Arcosa, Inc.
Audax Private Equity Fund V–A, L.P.; 3RC/Phoenix Investment, LLC; Audax Private Equity Fund V–A, L.P.
Golden Gate Capital Opportunity Fund. L.P.; VeriSign, Inc.; Golden Gate Capital Opportunity Fund. L.P.
Richard A. Robinson & Betti G. Robinson; O’Neal Industries, Inc.; Richard A. Robinson & Betti G. Robinson.
China National Chemical Corporation; Bonide Products, Inc.; China National Chemical Corporation.
AIA Oratam Sidecar LLC; Hudson Transmission Partners, LLC; AIA Oratam Sidecar LLC.
Mr. Cooper Group Inc.; Evan M. Stone; Mr. Cooper Group Inc.
Sun Capital Partners VI, LP.; Southfield Tier One Investment LP; Sun Capital Partners VI, LP.
Chesapeake Energy Corporation; WildHorse Resource Development Corporation; Chesapeake Energy Corporation.
Leggett & Platt Incorporated; Elite Comfort Solutions LP; Leggett & Platt Incorporated.
Sentinel Capital Partners VI, L.P.; Irving Place Capital Partners III SPV, L.P.; Sentinel Capital Partners VI, L.P.
Linden Capital Partners IV–A LP; Arlington Capital Partners III, L.P.; Linden Capital Partners IV–A LP.
Sycamore Partners III, L.P.; Newell Brands Inc.; Sycamore Partners III, L.P.
Klaus-Michael Kuhne; The Resolute Fund III, L.P.; Klaus-Michael Kuhne.
Chatchaval Jiaravanon; Meredith Corporation; Chatchaval Jiaravanon.
AIPCF VI Indirect Investor AIV LP; Armstrong Flooring, Inc.; AIPCF VI Indirect Investor AIV LP.
American Industrial Partners Capital Fund V, L.P.; Elkay Manufacturing Company; American Industrial Partners Capital
Fund V, L.P.
Open Text Corporation; LiaisonTechnologies, Inc.; Open Text Corporation.
Prime Communications, L.P.; GameStop Corp.; Prime Communications, L.P.
FOR FURTHER INFORMATION CONTACT:
Theresa Kingsberry, Program Support
Specialist, Federal Trade Commission
Premerger Notification Office, Bureau of
Competition, Room CC–5301,
Washington, DC 20024, (202) 326–3100.
By direction of the Commission.
April J. Tabor,
Acting Secretary.
[FR Doc. 2019–07735 Filed 4–17–19; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF DEFENSE
GENERAL SERVICES
ADMINISTRATION
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[OMB Control No. 9000–0070; Docket No.
2019–0003; Sequence No. 18]
Information Collection; Payments
Department of Defense (DOD),
General Services Administration (GSA),
and National Aeronautics and Space
Administration (NASA).
ACTION: Notice and request for
comments.
jbell on DSK30RV082PROD with NOTICES
AGENCY:
In accordance with the
Paperwork Reduction Act of 1995 and
the Office of Management and Budget
SUMMARY:
VerDate Sep<11>2014
17:37 Apr 17, 2019
Jkt 247001
(OMB) regulations, the FAR Council
invites the public to comment upon a
renewal regarding advanced payments.
DATES: Submit comments on or before:
June 17, 2019.
ADDRESSES: The FAR Council invites
interested persons to submit comments
on this collection by either of the
following methods:
• Federal eRulemaking Portal: This
website provides the ability to type
short comments directly into the
comment field or attach a file for
lengthier comments. Go to https://
www.regulations.gov and follow the
instructions on the site.
• Mail: General Services
Administration, Regulatory Secretariat
Division (MVCB), 1800 F Street NW,
Washington, DC 20405. ATTN: Ms.
Mandell/IC 9000–0070, Payments.
Instructions: Please submit comments
only and cite Information Collection
9000–0070, Payments, in all
correspondence related to this
collection. Comments received generally
will be posted without change to https://
www.regulations.gov, including any
personal and/or business confidential
information provided. To confirm
receipt of your comment(s), please
check www.regulations.gov,
approximately two-to-three days after
submission to verify posting (except
allow 30 days for posting of comments
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
submitted by mail). This information
collection is pending at the FAR
Council.
Mr.
Kevin Funk, Procurement Analyst, at
telephone 202–357–5805, or via email at
kevin.funk@gsa.gov.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
A. Solicitation of Public Comment
Written comments and suggestions
from the public should address one or
more of the following four points:
(1) Evaluate whether the collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information will have practical utility;
(2) Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
E:\FR\FM\18APN1.SGM
18APN1
Federal Register / Vol. 84, No. 75 / Thursday, April 18, 2019 / Notices
B. Purpose
Firms performing under Federal
contracts must provide adequate
documentation to support requests for
payment under these contracts. The
documentation may range from a simple
invoice to detailed cost data. The
information is usually submitted once,
at the end of the contract period or upon
delivery of the supplies or services, but
could be submitted more often
depending on the payment schedule
established under the contract (see
Federal Acquisition Regulation (FAR)
52.232–1 through FAR 52.232–4, FAR
52.232–6, 52.232–7, and 52.232–10).
jbell on DSK30RV082PROD with NOTICES
C. Annual Reporting Burden
Respondents: 1,724,163.
Responses per Respondent: 6.
Annual Responses: 10,344,978.
Hours per Response: 0.25.
Total Burden Hours: 2,586,245.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat Division (MVCB),
1800 F Street NW, Washington, DC
20405, at 202–501–4755. Please cite
OMB Control No. 9000–0070, Payments,
in all correspondence.
Dated: April 15, 2019.
Janet Fry,
Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2019–07816 Filed 4–17–19; 8:45 am]
BILLING CODE 6820–EP–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–1020]
Aurolife Pharma, LLC, et al.;
Withdrawal of Approval of 31
Abbreviated New Drug Applications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
withdrawing approval of 31 abbreviated
new drug applications (ANDAs) from
SUMMARY:
16269
multiple applicants. The applicants
notified the Agency in writing that the
drug products were no longer marketed
and requested that the approval of the
applications be withdrawn.
Approval is withdrawn as of
May 20, 2019.
DATES:
FOR FURTHER INFORMATION CONTACT:
Trang Tran, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 75, Rm. 1671, Silver Spring,
MD 20993–0002, 240–402–7945,
Trang.Tran@fda.hhs.gov.
The
applicants listed in the table have
informed FDA that these drug products
are no longer marketed and have
requested that FDA withdraw approval
of the applications under the process
described in § 314.150(c) (21 CFR
314.150(c)). The applicants have also,
by their requests, waived their
opportunity for a hearing. Withdrawal
of approval of an application or
abbreviated application under
§ 314.150(c) is without prejudice to
refiling.
SUPPLEMENTARY INFORMATION:
Application No.
Drug
Applicant
ANDA 070470 ...............
ANDA 070471 ...............
ANDA 070531 ...............
Disopyramide Phosphate Capsules USP, Equivalent to (EQ) 100 milligrams (mg) base.
Disopyramide Phosphate Capsules USP, EQ 150 mg base ................
Clofibrate Capsules USP, 500 mg ........................................................
ANDA 070797 ...............
ANDA 070956 ...............
Chlorpheniramine Maleate Extended-Release Capsules USP, 12 mg
Diazepam Tablets USP, 10 mg ............................................................
ANDA 071128 ...............
Haloperidol Tablets USP, 0.5 mg .........................................................
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
...............
...............
...............
...............
...............
...............
...............
...............
...............
Haloperidol Tablets USP, 1 mg ............................................................
Haloperidol Tablets USP, 20 mg ..........................................................
Fenoprofen Calcium Capsules USP, EQ 200 mg base .......................
Fenoprofen Calcium Capsules USP, EQ 300 mg base .......................
Fenoprofen Calcium Tablets USP, EQ 600 mg base ...........................
Trazodone Hydrochloride (HCl) Tablets USP, 50 mg ..........................
Ketoprofen Capsules, 50 mg and 75 mg ..............................................
Flurbiprofen Tablets USP, 50 mg and 100 mg .....................................
Pamidronate Disodium for Injection USP, 30 mg/vial and 90 mg/vial ..
ANDA 080655 ...............
ANDA 083234 ...............
Meprobamate Tablets USP, 400 mg ....................................................
Glutethimide Tablets, 500 mg ...............................................................
ANDA 084156 ...............
Pentobarbital Sodium Capsules, 100 mg .............................................
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
ANDA
Aminophylline Tables USP, 100 mg .....................................................
Sulfisoxazole Tablets USP, 500 mg .....................................................
Prednisone Tablets USP, 20 mg ..........................................................
Sulfamethoxazole Tablets USP, 500 mg ..............................................
Amitriptyline HCl Tablets USP, 50 mg ..................................................
Amitriptyline HCl Tablets USP, 75 mg ..................................................
Amitriptyline HCl Tablets USP, 100 mg ................................................
Cyproheptadine HCl Tablets USP, 4 mg ..............................................
Hydroxyzine HCl Tablets USP, 25 mg ..................................................
Quinidine Gluconate Extended-Release Tablets USP, 324 mg ...........
Prednisone Tablets USP, 10 mg ..........................................................
Aurolife Pharma, LLC, 279 Princeton
Hightstown Rd., East Windsor, NJ 08520.
Do.
Upsher-Smith Laboratories, LLC, 301 South
Cherokee St., Denver, CO 80223.
Aurolife Pharma, LLC.
Halsey Drug Co., Inc., 1827 Pacific St.,
Brooklyn, NY 11233.
Cycle Pharmaceuticals, Ltd., c/o Mapi USA,
Inc., 2343 Alexandria Dr., Suite 100, Lexington, KY 40504.
Do.
Do.
Aurolife Pharma, LLC.
Do.
Do.
Do.
Do.
Do.
Mustafa Nevzat Ilac San. A.S. (MN Pharmaceuticals), c/o Sagent Pharmaceuticals,
Inc., 1901 North Roselle Rd., suite 450,
Schaumburg, IL 60195.
Aurolife Pharma, LLC.
Upsher-Smith
Laboratories,
LLC,
6701
Evenstad Dr. North, Maple Grove, MN
55369.
Warner-Lambert Company, 201 Tabor Rd.,
Morris Plains, NJ 07950.
Halsey Drug Co., Inc.
Aurolife Pharma, LLC.
Do.
Do.
Halsey Drug Co., Inc.
Do.
Do.
Do.
Do.
Aurolife Pharma, LLC.
Do.
071129
071133
072394
072395
072396
072484
074024
074448
078300
084674
085628
085813
085844
085925
085926
085927
089057
089117
089894
089983
VerDate Sep<11>2014
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
17:37 Apr 17, 2019
Jkt 247001
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
E:\FR\FM\18APN1.SGM
18APN1
Agencies
[Federal Register Volume 84, Number 75 (Thursday, April 18, 2019)]
[Notices]
[Pages 16268-16269]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-07816]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
GENERAL SERVICES ADMINISTRATION
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
[OMB Control No. 9000-0070; Docket No. 2019-0003; Sequence No. 18]
Information Collection; Payments
AGENCY: Department of Defense (DOD), General Services Administration
(GSA), and National Aeronautics and Space Administration (NASA).
ACTION: Notice and request for comments.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Paperwork Reduction Act of 1995 and the
Office of Management and Budget (OMB) regulations, the FAR Council
invites the public to comment upon a renewal regarding advanced
payments.
DATES: Submit comments on or before: June 17, 2019.
ADDRESSES: The FAR Council invites interested persons to submit
comments on this collection by either of the following methods:
Federal eRulemaking Portal: This website provides the
ability to type short comments directly into the comment field or
attach a file for lengthier comments. Go to https://www.regulations.gov
and follow the instructions on the site.
Mail: General Services Administration, Regulatory
Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405.
ATTN: Ms. Mandell/IC 9000-0070, Payments.
Instructions: Please submit comments only and cite Information
Collection 9000-0070, Payments, in all correspondence related to this
collection. Comments received generally will be posted without change
to https://www.regulations.gov, including any personal and/or business
confidential information provided. To confirm receipt of your
comment(s), please check www.regulations.gov, approximately two-to-
three days after submission to verify posting (except allow 30 days for
posting of comments submitted by mail). This information collection is
pending at the FAR Council.
FOR FURTHER INFORMATION CONTACT: Mr. Kevin Funk, Procurement Analyst,
at telephone 202-357-5805, or via email at [email protected].
SUPPLEMENTARY INFORMATION:
A. Solicitation of Public Comment
Written comments and suggestions from the public should address one
or more of the following four points:
(1) Evaluate whether the collection of information is necessary for
the proper performance of the functions of the agency, including
whether the information will have practical utility;
(2) Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(3) Enhance the quality, utility, and clarity of the information to
be collected; and
(4) Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submission of responses.
[[Page 16269]]
B. Purpose
Firms performing under Federal contracts must provide adequate
documentation to support requests for payment under these contracts.
The documentation may range from a simple invoice to detailed cost
data. The information is usually submitted once, at the end of the
contract period or upon delivery of the supplies or services, but could
be submitted more often depending on the payment schedule established
under the contract (see Federal Acquisition Regulation (FAR) 52.232-1
through FAR 52.232-4, FAR 52.232-6, 52.232-7, and 52.232-10).
C. Annual Reporting Burden
Respondents: 1,724,163.
Responses per Respondent: 6.
Annual Responses: 10,344,978.
Hours per Response: 0.25.
Total Burden Hours: 2,586,245.
Obtaining Copies of Proposals: Requesters may obtain a copy of the
information collection documents from the General Services
Administration, Regulatory Secretariat Division (MVCB), 1800 F Street
NW, Washington, DC 20405, at 202-501-4755. Please cite OMB Control No.
9000-0070, Payments, in all correspondence.
Dated: April 15, 2019.
Janet Fry,
Director, Federal Acquisition Policy Division, Office of Governmentwide
Acquisition Policy, Office of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2019-07816 Filed 4-17-19; 8:45 am]
BILLING CODE 6820-EP-P